UCLA_Integrated_Staging_System_UISS_for_Renal_Cell_Carcinoma_RCC_guideline v.1
UCLA Integrated Staging System (UISS) for Renal Cell Carcinoma (RCC) provides 5-year disease-free prognosis for localized and metastatic RCC.
To provide 5-year disease-free prognosis for localized and metastatic RCC.
Use for patients with RCC, localized or metastatic, particularly those being considered for clinical trial enrollment. Variables: Localized: Any T; N0; M0 Metastatic: T>0; N>1; M>1 For accurate staging, see the TNM Staging for RCC. This score placed patients with local or metastatic renal cell carcinoma (mRCC) into mortality risk groups: low, intermediate/moderate, and high. FORMULA: Addition of the selected points. Interpretation: Disease Type: Local Disease = Low Risk Group= 91.1% Five-year disease-specific survival Disease Type: Local Disease = Intermediate Risk Group= 80.4% Five-year disease-specific survival Disease Type: Local Disease = High Risk Group= 54.7% Five-year disease-specific survival Disease Type: Metastatic Disease = Low Risk Group= 32% Five-year disease-specific survival Disease Type: Metastatic Disease = Intermediate Risk Group= 19.5% Five-year disease-specific survival Disease Type: Metastatic Disease = High Risk Group= 0% Five-year disease-specific survival
1. Zisman A,Pantuck AJ,Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002; 20: 4559–4566. 2. Patard J, et al. Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study. JCO Aug 15, 2004:3316-3322 3. Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012; 23(suppl 7):vii65–vii71.
OBSERVATION.ucla_integrated_staging_system_uiss_for_renal_cell_carcinoma_rcc.v0
